Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 863, Issue 2, 2008, Pages 258-265

  McCulloch, Melissa ^a   Zhou, Xiang ^a   Xu, Yan ^a   Brunell, Steve ^b   Spear, Linda ^b  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b BINGHAMTON UNIVERSITY   (United States)

Author keywords

Endocannabinoid receptor antagonist; Human and rat plasma; LC ESI MS MS; Rimonabant; SR141716

Indexed keywords

BRAIN; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTEINS;

ENDOCANNABINOID RECEPTOR ANTAGONIST; TANDEM MASS SPECTROMETRY;

PLASMA (HUMAN);

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; RIMONABANT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROSPRAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANIMALS; AREA UNDER CURVE; CALIBRATION; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; ENDOCANNABINOIDS; FEASIBILITY STUDIES; HUMANS; PIPERIDINES; PYRAZOLES; QUALITY CONTROL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

ANIMALIA; RATTUS;

EID: 39749094922     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.01.020     Document Type: Article

References (19)

1. Rinaldi-Carmona M., Barth F., and Héaulme M. FEBS Lett. 350 (1994) 240
2. Di Marzo V., Bifulco M., and De Petrocellis L. Nat. Rev. Drug Discov. 3 (2004) 771
3. Pertwee R.G. Pharmacol. Ther. 74 (1997) 129
4. McAllister S.D., Griffin G., Satin L.S., and Abood M.E. J. Pharmacol. Exp. Ther. 291 (1999) 618
5. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., and Mitchell R.L. Mol. Pharmacol. 48 (1995) 443
6. Bouaboula M., Poinot-Chazel C., Bourrié B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., and Casellas P. Biochem. J. 312 (1995) 637
7. McAllister S.D., and Glass M. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 161
8. Navarro M., Carrera M., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gómez R., Villanúa M., Maldonado R., Koob G., and Rodríguez de Fonseca F. J. Neurosci. 21 (2001) 5344
9. De Vries T., Shaham Y., Homberg J., Crombag H., Schuurman K., Dieben J., Vanderschuren L., and Schoffelmeer A. Nat. Med. 7 (2001) 1151
10. Cohen C., Perrault G., Voltz C., Steinberg R., and Soubrie P. Behav. Pharmacol. 13 (2002) 451
11. Colombo G., Vacca G., and Serra S. Eur. J. Pharmacol. 498 (2004) 119
12. Carai M., Colombo G., Gessa G., and Gian L. Life Sci. 77 (2005) 2339
13. Di Marzo V., and Matias I. Nat. Neurosci. 8 (2005) 585
14. ClinicalTrials.gov Identifier: NCT00075205.
15. ClinicalTrials.gov Identifier: NCT00449605.
16. ClinicalTrials.gov Identifier: NCT00386061.
17. Grozav A., Hutson T., Zhou X., Bukowski R., Ganapathi R., and Xu Y. J. Pharm. Biomed. Anal. 36 (2004) 125
18. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf
19. Hsieh Y., Duncan C.J.G., and Brisson J.-M. Anal. Chem. 79 (2007) 5668